Journals / Ağrı / 2009 / Cilt: 21 - Sayı: 3

Servikal miyofasiyal ağrı sendromunun tedavisinde topikal tiyokolşikosid'in (Muscoril®) etkinliği: Tek-kör, randomize, prospektif, faz IV klinik çalışma

The efficacy of topical thiocolchicoside (Muscoril®) in the treatment of acute cervical myofascial pain syndrome: A single-blind, randomized, prospective, phase IV clinical study

Journal
Ağrı
Pages
95–103
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

The ointment form may be a good alternative, particularly in patients who cannot receive injections.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objectives: Myofascial pain syndrome is a disorder characterized by hypersensitive sites called trigger points at one or more muscles and/or connective tissue, leading to pain, muscle spasm, sensitivity, rigor, limitation of movement, weakness, and rarely, autonomic dysfunction.
📊
Key Findings & Data:The first group received thiocolchicoside ointment onto the trigger points, the second group received 8 mg thiocolchicoside intramuscular injection to the trigger points, and the third group received both treatments.
💡
Conclusion & Impact:The ointment form may be a good alternative, particularly in patients who cannot receive injections.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Objectives: Myofascial pain syndrome is a disorder characterized by hypersensitive sites called trigger points at one or more muscles and/or connective tissue, leading to pain, muscle spasm, sensitivity, rigor, limitation of movement, weakness, and rarely, autonomic dysfunction. Various treatment methods have been used in the treatment of myofascial pain syndrome. Among these, stretch and spray technique, trigger point injection, dry needling, pharmacological agents, and physical therapy modalities have been proven effective. Methods: Sixty-five patients with acute myofascial pain syndrome were recruited into the study. Patients were randomized into three groups. The first group received thiocolchicoside ointment onto the trigger points, the second group received 8 mg thiocolchicoside intramuscular injection to the trigger points, and the third group received both treatments. Treatment was applied for 5 consecutive days. Algometric and goniometric measurements and pain severity assessments with visual analog scale (VAS) were repeated on the first, third, and fifth days of the treatment. Results: Pain severity measured with VAS significantly improved after the first day in the mono-therapy groups and after the third day in all groups. While significant improvement was observed in all three groups in right lateral flexion measurements, no significant changes were observed in the combined treatment group in left lateral flexion measurements. Conclusion: Thiocolchicoside can be used in the treatment of myofascial pain syndrome. The ointment form may be a good alternative, particularly in patients who cannot receive injections.

Özet

Amaç: Miyofasiyal ağrı sendromu, bir veya birkaç kas ve/veya bağ dokusunda bulunan ve tetik nokta denilen hipersensitif bölgelerle kendini gösteren; ağrı, kas spazmı, hassasiyet, sertlik, hareket kısıtlılığı, güçsüzlük ve nadiren otonomik disfonksiyon yapabilen bir rahatsızlıktır. Miyofasiyal ağrı sendromunun tedavisinde çeşitli tedavi yöntemleri kullanılmıştır. Bu tedaviler arasında germe ve sprey tekniği, tetik nokta enjeksiyonu, kuru iğneleme, çeşitli ilaç tedavileri ve fizik tedavi yöntemlerinin etkinliği gösterilmiştir. Gereç ve Yöntem: Çalışmaya akut miyofasiyal ağrı sendromulu 65 hasta alındı. Hastalar üç gruba randomize edildi. İlk gruba tetik noktalar üzerine tiyokolşikosid merhem, ikinci gruba tetik noktalar üzerine tiyokolşikosid ampul intramuskuler, üçüncü gruba ikisi birlikte uygulandı. Tedaviler beş gün boyunca yapıldı. Algometrik ve goniometrik ölçümler, vizüel analog skala (VAS) ile ağrı şiddeti değerlendirimi birinci, üçüncü ve beşinci günde yapıldı. Bulgular: VAS ile ölçülen ağrı şiddeti birinci günden itibaren monoterapi gruplarında, üçüncü günden itibaren tüm gruplarda anlamlı oranda düştü. Her üç grupta da sağa lateral fleksiyonda anlamlı düzelme gözlenirken, kombine tedavi grubunda sola lateral fleksiyonda anlamlı düzelme saptanmadı. Sonuç: Tiyokolşikosid, miyofasiyal ağrı sendromu tedavisinde kullanılabilir ve merhem formu özellikle enjeksiyon uygulanamayan hastalar için iyi bir alternatif oluşturabilir.

🔖

Cite This Article

KETENCİ, A., BASAT, H., ESMAEİLZADEH, S. (2009). Servikal miyofasiyal ağrı sendromunun tedavisinde topikal tiyokolşikosid'in (Muscoril®) etkinliği: Tek-kör, randomize, prospektif, faz IV klinik çalışma. Ağrı, Cilt: 21 - Sayı: 3, 95–103. https://ajindex.com/articles/197545

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (16)

  1. Sola AE, Bonica JJ. Myofascial pain syndromes. In: Bonica JJ, editor. The management of pain. 2nd ed. Malvern: Lea & Febiger; 1990. p. 352-67
  2. Han SC, Harrison P. Myofascial pain syndrome and triggerpoint management. Reg Anesth 1997;22:89-101
  3. Taylor H. The Nuprin Report. New York: Lou Harris Associates; 1985
  4. Travell JG, Simons DG. Myofascial pain and dysfunction. The Trigger Point Manual. Baltimore: Williams &Wilkins; 1992
  5. Skootsky SA, Jaeger B, Oye RK. Prevalence of myofascial pain in general internal medicine practice. West J Med 1989;151:157-60
  6. Magni G. The epidemiology of musculoskeletal pain. In: Voeroy H, Merskey H, editors. Progress in fibromyalgia and myofascial pain. Amsterdam: Elsevier Science; 1993. p. 3-20
  7. Porta M. Treatment of myofascial pain by injection with botilinum toxin. Bollington: Adelphi Communications Ltd; 1997
  8. Thompson JM. The diagnosis and treatment of muscle pain syndromes. In: Braddom RL, editor. Physical medicine and rehabilitation. Philadelphia: Saunders Company; 1996. p. 893-914
  9. Simons DG. Myofascial pain syndromes: where are we? Where are we going? Arch Phys Med Rehabil 1988;69(3 Pt 1):207-12
  10. Simons DG, Travell JG. Myofascial pain syndromes. In: Wall PD, Melzack R, editors. Textbook of Pain. New York: Churchill Livingstone; 1989. p. 368-85
  11. Ojala T, Arokoski JP, Partanen J. The effect of small doses of botulinum toxin a on neck-shoulder myofascial pain syndrome: a double-blind, randomized, and controlled crossover trial. Clin J Pain 2006;22:90-6
  12. Qerama E, Fuglsang-Frederiksen A, Kasch H, Bach FW, Jensen TS. A double-blind, controlled study of botulinum toxin A in chronic myofascial pain. Neurology 2006;67:241-5
  13. Kamanli A, Kaya A, Ardicoglu O, Ozgocmen S, Zengin FO, Bayik Y. Comparison of lidocaine injection, botulinum toxin injection, and dry needling to trigger points in myofascial pain syndrome. Rheumatol Int 2005;25:604-11
  14. Porta M. A comparative trial of botulinum toxin type A and ethylprednisolone for the treatment of myofascial pain syndrome and pain from chronic muscle spasm. Pain 2000;85:101-5
  15. Patat A, Klein MJ. Effects of acute and repeated doses of two muscle relaxants chlormezanone and thiocolchicoside, on vigilance and psychomotor performance of healthy volunteers. Hum Psychopharmacol 1991;6:285-92
  16. Janbroers JM. Review of the toxicology, pharmacodynamics and pharmacokinetics of thiocolchicoside, a GABA-agonist muscle-relaxant with anti-inflammatory